The Immune System as a PFAS Target Organ
Among the many biological systems affected by PFAS exposure, the immune system has emerged as one of the most consistently impacted endpoints across epidemiological studies, animal experiments, and mechanistic investigations. The immune-suppressive effects of PFAS were initially documented in occupationally exposed worker cohorts and in heavily contaminated communities such as the Faroe Islands, where children with high prenatal PFAS exposure showed markedly reduced antibody titers following routine diphtheria and tetanus vaccinations. Subsequent research has expanded and refined the initial findings, establishing a progressively more detailed picture of how PFAS interact with immune signaling, lymphocyte development, and the inflammatory response.
Between 2023 and 2025, a substantial body of new research has further consolidated the evidence base, extended the list of implicated PFAS compounds beyond PFOA and PFOS, and begun to elucidate the mechanistic pathways through which PFAS impair specific immune functions. This research has direct implications for public health policy, because immune suppression — unlike many other PFAS health endpoints — has population-level consequences that extend to infectious disease susceptibility, vaccine program effectiveness, and autoimmune disease risk.
Vaccine Immune Response: Extended Compound Attribution
The most robust and replicated immune endpoint in the PFAS literature is attenuation of vaccine antibody response. 2023–2025 meta-analyses have pooled data from prospective birth cohort studies across multiple continents to assess which PFAS compounds are most consistently associated with reduced vaccine antibody titers in children. While PFOA and PFOS retain the strongest evidence base, recent analyses have identified PFHxS and PFNA as significant contributors to vaccine immune suppression in mixture analyses that account for co-exposure between compounds.
A 2024 meta-analysis covering twelve cohort studies found that each doubling of prenatal PFHxS exposure was associated with a 9–14% reduction in tetanus toxoid antibody titers at 12–18 months of age, after adjustment for PFOA and PFOS. PFNA showed a similar magnitude of association for diphtheria antibody titers. These effect sizes, while modest in absolute terms, translate to meaningful population-level increases in vaccine non-response rates in PFAS-exposed communities. The finding that multiple PFAS compounds independently contribute to vaccine immune suppression — after mutual adjustment — is consistent with mixture additivity and strengthens the case for multi-compound exposure assessment.
Mechanistic Pathways: What the Newer Research Shows
Mechanistic research from 2023–2025 has added cellular and molecular detail to the population-level associations. In vitro and animal studies have identified several pathways through which PFAS alter immune function: PPARα-mediated suppression of cytokine production in macrophages; disruption of T-cell receptor signaling affecting lymphocyte proliferation and differentiation; alteration of natural killer (NK) cell cytotoxic activity; and interference with dendritic cell antigen presentation functions critical for initiating adaptive immune responses.
Of particular mechanistic interest is the finding that PFAS disrupt the thymus — the organ responsible for T-cell maturation — in animal models. Gestational PFAS exposure has been shown to reduce thymic cellularity, alter the ratio of helper-to-suppressor T cells, and impair the selection processes that eliminate autoreactive T cells. This thymic disruption could theoretically contribute to both the immune suppression observed in vaccine studies and the elevated autoimmune disease associations reported in some PFAS epidemiology literature. The bridge between these mechanistic animal findings and human epidemiological outcomes remains an active area of investigation.
Implications for Risk Assessment and Public Health
The 2023–2025 immune function literature reinforces several key points for risk assessment. First, immune suppression is detectable at serum PFAS concentrations within the range of the general U.S. population, not only in highly contaminated communities. NHANES data analysis linking serum PFAS to vaccine antibody response in U.S. children found associations at exposures reflecting the upper end of the general population distribution — suggesting that the affected population is not a rare, high-exposure subgroup but a meaningful fraction of the child population.
Second, the immune endpoint is particularly challenging for regulatory risk assessment because the health consequence — increased susceptibility to infectious disease or attenuated vaccine protection — does not manifest as a diagnosable individual condition directly attributable to PFAS exposure. Rather, it increases the probability of adverse outcomes that have multiple causes. This diffuse causation makes individual-level attribution difficult but does not diminish the population-level public health burden. Third, the extension of immune findings to PFHxS and PFNA, in addition to PFOA and PFOS, further supports the scientific rationale for multi-compound regulatory approaches rather than single-compound MCLs evaluated in isolation.